TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00659334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosurgery
Description: neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neurosurgery
Description: neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosurgery
Description: neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neurosurgery
Description: neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
Study: NCT00253864

Intervention type: PROCEDURE
Intervention: Single row
Description: Fixation type in arthroscopic rotator cuff repair.

Intervention type: PROCEDURE
Intervention: Double row
Description: Fixation type in arthroscopic rotator cuff repair.
Study: NCT02099734

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: OTHER
Intervention: sample of blood or saliva
Description: A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.

Intervention type: OTHER
Intervention: sample of blood or saliva
Description: A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.

Intervention type: OTHER
Intervention: sample of blood or saliva
Description: A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
Study: NCT03186963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No immobilization
Description: Conventional wrist dressing
Study: NCT01359553

Intervention type: OTHER
Intervention: Intra-articular ultrasound imaging of knee joint during arthroscopy

Intervention type: OTHER
Intervention: Non-invasive ultrasound imaging of knee

Intervention type: OTHER
Intervention: Quantitative MRI imaging of knee

Intervention type: OTHER
Intervention: Contrast-enhanced CT imaging of knee
Study: NCT05262153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgically performed scaling and root planing
Description: Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgically performed scaling and root planing
Description: Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
Study: NCT03792113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Flap Surgery
Description: Periodontal access flap surgery will be performed in both test site followed by control site in each subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Flap Surgery
Description: Periodontal access flap surgery will be performed in both test site followed by control site in each subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Description: Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4-0 silk suture
Description: Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
Study: NCT01316926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Study: NCT03186963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar splint
Description: Volar plaster splint
Study: NCT01124526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Fludarabine Cyclophosphamide
Description: Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)
Study: NCT03223285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Treatment Group
Description: Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment Group
Description: Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques
Study: NCT01316926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Study: NCT01815177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic transosseous fixation
Study: NCT06568133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UIC201603 and co-administration of UIC201603 and UIC201604
Description: * UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UIC201604 and co-administration of UIC201603 and UIC201604
Description: * UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604
Study: NCT01815177

Intervention type: DEVICE
Group type: OTHER
Intervention: Suture anchors
Study: NCT02909972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924 in combination with cytarabine
Description: Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
Study: NCT01329029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 µg, once daily
Study: NCT05100849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinect-based cognitive training
Description: The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tablet-based cognitive training
Description: The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
Study: NCT02593890

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THEYA Recovery Range
Description: Post-operative Lingerie made from viscose derived bamboo
Study: NCT01692418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: 1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline will be administered as an i.v. infusion (100ml normal saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered as an i.v. infusion (100ml normal saline)
Study: NCT02551302

Intervention type: DEVICE
Group type: OTHER
Intervention: Solera™ Medtronic
Description: The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic

Intervention type: DEVICE
Group type: OTHER
Intervention: CD HORIZON BalanC™ Medtronic
Description: The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic
Study: NCT00068445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT01175161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T380A Intrauterine Device
Description: the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T380A Intrauterine Device
Description: the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
Study: NCT04175678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
Study: NCT01329029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT03094572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual motor tasks
Description: This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game.
Study: NCT04175678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
Study: NCT04402177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Prednisolonate
Description: Corticosteroid treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Prednisolonate
Description: Corticosteroid treatment
Study: NCT00919269

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01751022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Description: Implant and follow-up of study lead, separate analysis for each lead model
Study: NCT02171468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran low dose
Study: NCT01257867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithia water
Description: Oral intake of approximately 2 litres (2L) daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Natural spring water with negligible lithium levels
Description: Oral intake of approximately 2 litres (2L) daily for 4 weeks
Study: NCT01932164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary alveolar graft by tissue engineering
Description: Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone tissue engineering using mesenchymal stem cells
Description: Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
Study: NCT01034124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin, vitamin K, midazolam
Description: warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: warfarin, vitamin K, midazolam
Description: warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
Study: NCT02632578

Intervention type: BIOLOGICAL
Intervention: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)
Description: Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.

Intervention type: BIOLOGICAL
Intervention: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)
Description: Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
Study: NCT01389973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Description: Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Description: Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg
Description: Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 180 mg
Description: Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
Study: NCT04915794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation of preeclamptic pregnancy care
Description: It is an important step in providing safe care to patients, as a learning environment is provided in which environmental risks are minimized with simulation applications. Simulation-based trainings are environments that allow each student to learn, equitable, based on adult learning principles, and open to different learning styles. In these environments, interests and needs are defined together by the learner and the educator. By keeping the experiences of the learner at the forefront, the opportunity is given to learn by doing and is supported with feedback.
Study: NCT02943746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protein Diet
Description: Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
Study: NCT00651508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KOS-1584
Description: 25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
Study: NCT02863562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises
Description: Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises
Description: Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Kinesio taping
Study: NCT03415620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
Study: NCT04175678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Observational

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Observational
Study: NCT03799874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide at 200 ppm
Description: Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Medical air
Description: Inhaled Medical Air for up to 90 minutes daily for 3 days.
Study: NCT01340274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT treatment
Description: Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
Study: NCT04304235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Rapid Sepsis Trigger (PRST) tool
Description: The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Triage and Treatment (ETAT) guidelines
Description: These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
Study: NCT00577954

Intervention type: PROCEDURE
Intervention: Multimodal MRI
Description: Multimodal MRI